Angela Dispenzieri MD

Professor, Internal Medicine, Mayo Medical School

200 1st St SwRochester, MN 55905
Phone+1 507-284-2511

Dr. Dispenzieri is on Doximity

As a Doximity member, you’ll join more than three million U.S. healthcare professionals—including 85+% of physicians, and 2/3 of all NPs and PAs—in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Dispenzieri's full profile Already have an account?

Summary

Dr. Angela Dispenzieri is a hematologist in Rochester, MN and is affiliated with Mayo Clinic Hospital - Rochester. She received her medical degree from Albert Einstein College of Medicine and has been in practice 26 years. She is experienced in hematopoietic stem cell transplantation, multiple myeloma, POEMS syndrome, and mass spectrometry.

Education & Training

Mayo Clinic College of Medicine and Science (Rochester)Fellowship, Hematology and Medical Oncology, 1994 - 1998
Mayo Clinic College of Medicine and Science (Rochester)Residency, Internal Medicine, 1991 - 1994
Albert Einstein College of MedicineClass of 1991
Massachusetts Institute of TechnologyB.S., Biology, 1981 - 1985

The following disclaimer is related to board certifications obtained from ABMS®, denoted by the ABMS® logo.

This information is proprietary data maintained in a copyrighted database owned by the American Board of Medical Specialties®. The display and presence of ABMS Data in no way constitutes any affiliation, association with, or endorsement of any advertising, promotion, or sponsorship by ABMS and its affiliates and subsidiaries, the ABMS Member Boards, or ABMS board certified physicians and medical specialists. Copyright 2026 American Board of Medical Specialties®. All rights reserved.

The user is responsible for ensuring that the profile obtained in this directory is the profile of the physician or medical specialist being sought.

A self-designated specialty, subspecialty, or practice area neither implies nor is equivalent to ABMS board certification or the existence of specialized training by or competence of a physician or medical specialist.

Certifications & Licensure

MN State Medical License 1992 - 2027
American Board of Internal Medicine Hematology

Awards, Honors, & Recognition

CMS Meaningful Use Stage 1 Certification Centricity Enterprise (CE), GE Healthcare, 2014-2017
CMS Meaningful Use Stage 2 Certification Mayo Clinic Patient Lists, Mayo Clinic, 2014-2017
CMS Meaningful Use Stage 2 Certification Centricity Patient Online, GE Healthcare, 2014-2017

Clinical Trials

Iododoxorubicin in Treating Patients With Primary Systemic Amyloidosis
TERMINATED
PHASE1
Flavopiridol in Treating Patients With Relapsed or Refractory Multiple Myeloma
COMPLETED
PHASE2
Efficacy of CC-5013 (Revlimid or Lenalidomide) in Patients With Primary Systemic Amyloidosis
COMPLETED
PHASE2

Publications & Presentations

PubMed

Patterns of Progression and Clinical Outcomes After First Progression in Patients With Primary Plasma Cell Leukemia.
Daniel G Packard, Shaji K Kumar, Angela Dispenzieri, Prashant Kapoor, Guneet Janda
American Journal of Hematology. 2026-09-01
Persistence of M-proteins detected by mass spectrometry.
David L Murray, Jonathan Coker, Taxiarchis Kourelis, Angela Dispenzieri, Mindy Kohlhagen
Blood Cancer Journal. 2026-08-20
Utility of Prognostic Staging Systems in Transthyretin Amyloidosis Cardiomyopathy in the Era of Available Disease-Modifying Treatment.
Jens K Skov, Tor S Clemmensen, Christopher G Scott, Omar F Abou Ezzedine, Ian C Chang
Journal of the American Heart Association. 2026-08-18

Journal Articles

Systemic Amyloidosis Recognition, Prognosis, and Therapy
Morie A Gertz, Angela Dispenzieri, JAMA
Impact of Prior Diagnosis of Monoclonal Gammopathy on Outcomes in Newly Diagnosed Multiple Myeloma
S Vincent Rajkumar, Yi L Hwa, Wilson I Gonsalves, Francis K Buadi, Angela Dispenzieri, Prashant Kapoor, Miriam A Hobbs, Martha Q Lacy, John A Lust, Robert A Kyle, Mori..., Nature
Safety and Efficacy of Propylene Glycol-Free Melphalan as Conditioning in Patients with AL Amyloidosis Undergoing Stem Cell Transplantation
Nelson Leung, Prashant Kapoor, Taxiarchis V Kourelis, Eli Muchtar, Angela Dispenzieri, M Hasib Sidiqi, Martha Q Lacy, Wilson I Gonsalves, Shaji K Kumar, Mohammed A Alj..., Nature

Books/Book Chapters

Abeloff's Clinical Oncology
Chapter: Multiple Myeloma and Related Disorders
Page 1991 - 2017Rajkumar SV, Dispenzieri AEditors: Niederhuber JE; et al.Churchill Livingstone, PhiladelphiaEdition Fift,2014
Multiple Myeloma: Diagnosed and Treatment
Chapter: POEMS Syndrome (Takatsuki Syndrome)
Page 179 - 193Dispenzieri AEditors: Gertz MA; Rajkumar SV.Springer, New York2014
Myeloma-Pathology, Diagnosis, and Treatment
Chapter: POEMS Syndrome and Paraproteinemic Syndromes: Management and Follow-up
Page 225 - 243Dispenzieri A , Hayman SEditors: Schey SA, Yong KL, Marcus R, Anderson KC.Cambridge University Press, New YorkEdition 1st,2014

Abstracts/Posters

Optimal Therapy for Relapsed AL Amyloidosis Post Autologous Stem Cell Transplant
Angela Dispenzieri, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Patient Experience of Chimeric Antigen Receptor (CAR)-T Cell Therapy Vs. Stem Cell Transplant: Longitudinal Patient Reported Adverse Events, Cognition and Quality of Life
Angela Dispenzieri, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Glycosylation of Immunoglobulin Light Chains Is Highly Prevalent in Cold Agglutinin Disease
Angela Dispenzieri, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019

Lectures

Monoclonal Gammopathies of Cutaneous, Neuropathic, and Renal Significance
61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
Serum BCMA levels to predict outcomes for patients with MGUS and smoldering multiple myeloma (SMM).
2019 ASCO Annual Meeting - 6/1/2019
Ixazomib, lenalidomide, and dexamethasone for patients with POEMS syndrome.
2019 ASCO Annual Meeting - 6/1/2019

Other

Primary Amyloidosis
European School of Oncology Website
8/1/2013
Treatment Paradigms of Multiple Myeloma: Do Emerging Therapies Offer an Advantage
Live CME Certified, Satellite Broadcast
Chicago, Illinois - 9/1/2006
Multiple Myeloma Module
Dispenzieri A, PIER for the ACP
1/1/2003

Authored Content

Systemic Amyloidosis Recognition, Prognosis, and TherapyJuly 2020
Systemic Amyloidosis Recognition, Prognosis, and TherapyJuly 2020

Press Mentions

Mayo Clinic Research in the News — 8/9/2021August 10th, 2021
Predictors of Short-Term Survival in Waldenström MacroglobulinemiaJuly 14th, 2020
Takeda Provides Update on TOURMALINE-MM2 Phase 3 TrialMarch 10th, 2020